February 24, 2023
Recently, the University of Oxford began an international study to examine the potential therapeutic benefits of cannabidiol (CBD) in treating psychosis or psychotic symptoms.
February 20, 2023
The House and Senate introduced a revised bill to mandate Veterans Affairs (VA) to conduct research on the effects of medical cannabis on veterans with post-traumatic stress disorder (PTSD) and chronic pain.
February 15, 2023
Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.
February 09, 2023
Starting July 1, 2023, Australia will allow the use of psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA) for therapeutic use in a medical setting to treat mental health conditions.
February 06, 2023
On February 2nd, Americans for Safe Access (ASA) held an editorial/press briefing to present their 2022 State of the States report, which graded each US state and four territories on patient access to cannabis. ASA is the nation’s largest member-based organization promoting safe and legal access to cannabis for therapeutic use and research.
January 27, 2023
A statement released on Thursday, January 26, 2023 from Dr. Janet Woodcock, the principal deputy commissioner of the Food and Drug Administration (FDA), announced that the FDA will work with Congress in formulating regulatory oversight to balance risk and access for products in the cannabidiol (CBD) market.
January 26, 2023
As access to edible cannabis increases for adults across the United States, children are also becoming more exposed as well.
Results from recently published survey studies on the effect of psilocybin and bipolar disorder offered support for the design of future clinical trials.
This 1 CME credit article evaluates evidence-based behavioral treatments, medications, and management strategies for cannabis use disorder.
A study published in January 2023 examined the effects of high and low doses of cannabigerol (CBG) on mice liver.